We found that the AML patients with the higher percentage of CD4+ PD1+ in peripheral blood had shorter OS than those with the lower percentage (median 90 vs 525 days, p = 0.0005) (Fig. 7A). This evidence concerns the gene PDCD1 and acute myeloid leukemia.